Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 993.86M |
| Revenue (ttm) | 294.22M |
| Net Income (ttm) | 1.84M |
| Shares Out | 67.52M |
| EPS (ttm) | 0.01 |
| PE Ratio | 1,472.00 |
| Forward PE | 19.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 936,701 |
| Open | 14.87 |
| Previous Close | 14.75 |
| Day's Range | 14.40 - 15.13 |
| 52-Week Range | 11.82 - 41.93 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 41.50 (+181.93%) |
| Earnings Date | Nov 9, 2023 |
About AMLX
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is h... [Read more]
Financial Performance
In 2022, AMLX's revenue was $22.23 million, an increase of 7700.00% compared to the previous year's $285,000. Losses were -$198.38 million, 125.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price forecast is $41.5, which is an increase of 181.93% from the latest price.
News
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX
NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX). Such investors are adv...
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS.
These biotechs targeting multiple neurodegenerative diseases
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive...
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer.
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND.
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference.
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or th...
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX)
NEW YORK--(BUSINESS WIRE)---- $AMLX #classactionlawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ:...
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results.
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023.
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals announces a presentation at Neuro2023 on the design of ORION, a planned global, Phase 3 clinical trial of AMX0035 in PSP.
Amylyx Pharmaceuticals shares fall after ALS treatment is rejected by European regulator
Amylyx Pharmaceuticals Inc. AMLX, -4.60% shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its negative opinion on Albrioza, a treatment for amyot...
EU regulator declines to recommend Amylyx' ALS drug
Amylyx Pharmaceuticals said on Friday the European Union medicines regulator for the second time declined to recommend a marketing authorisation for the company's drug to treat amyotrophic lateral scl...
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its MAA for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination.
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals announced the publication of a post hoc analysis of survival data from the CENTAUR study.
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France.
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. announced the acceptance of several abstracts for presentation at the 2023 Northeast ALS Consortium Annual Meeting.
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate at two upcoming investor conferences on September 11-12.
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results.
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals announces it will report its second quarter 2023 financial results on Thursday, August 10, 2023.
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Webcast to Discuss the PSP Treatment Landscape and the Company's Clinical Development Plans on July 26, at 1:30pm ET.
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 - Will Seek Re-Examination.
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx signs LOI with the pCPA for ALBRIOZA™ and will now work with drug plans to ensure public coverage to eligible Canadians with ALS.